Active Methamphetamine Use is Associated with Transmitted Drug Resistance to Non-nucleoside Reverse Transcriptase Inhibitors in Individuals with HIV Infection of Unknown Duration

Overview

Journal Open AIDS J

Publisher Bentham Open

Specialty Infectious Diseases

Date 2008 Oct 17

PMID 18923691

Citations 10

Authors

Edward R Cachay

Niousha Moini

Sergei L Kosakovsky Pond

Rick Pesano

Yolanda S Lie

Heidi Aiem

David M Butler

Scott Letendre

Wm Christopher Mathews

Davey M Smith

Affiliations

Soon will be listed here.

Abstract

Background: Frequent methamphetamine use among recently HIV infected individuals is associated with transmitted drug resistance (TDR) to non-nucleoside reverse transcriptase inhibitors (NNRTI); however, the reversion time of TDR to drug susceptible HIV may exceed 3 years. We assessed whether recreational substance use is associated with detectable TDR among individuals newly diagnosed with HIV infection of unknown duration.

Design: Cross-sectional analysis.

Methods: Subjects were enrolled at the University California, San Diego Early Intervention Program. Demographic, clinical and substance use data were collected using structured interviews. Genotypic resistance testing was performed using GeneSeq, Monogram Biosciences. We analyzed the association between substance use and TDR using bivariate analyses and the corresponding transmission networks using phylogenetic models.

Results: Between April 2004 and July 2006, 115 individuals with genotype data were enrolled. The prevalence of alcohol, marijuana and methamphetamine use were 98%, 71% and 64% respectively. Only active methamphetamine use in the 30 days prior to HIV diagnosis was independently associated with TDR to NNRTI (OR: 6.6; p=0.002).

Conclusion: Despite not knowing the duration of their HIV infection, individuals reporting active methamphetamine use in the 30 days prior to HIV diagnosis are at an increased risk of having HIV strains that are resistant to NNRTI.

Citing Articles

Accumulation of HIV-1 Drug Resistance Mutations and Methamphetamine Use.

Truong H, Fatch R, Deeks S, Krone M, Martin J, Hunt P Curr HIV Res. 2021; 19(6):497-503.

PMID: 34176462 PMC: 10659984. DOI: 10.2174/1570162X19666210625103902.

Methamphetamine Enhances HIV-1 Replication in CD4 T-Cells via a Novel IL-1β Auto-Regulatory Loop.

Lawson K, Prasad A, Groopman J Front Immunol. 2020; 11:136.

PMID: 32117283 PMC: 7025468. DOI: 10.3389/fimmu.2020.00136.

The Complex Interaction Between Methamphetamine Abuse and HIV-1 Pathogenesis.

Passaro R, Pandhare J, Qian H, Dash C J Neuroimmune Pharmacol. 2015; 10(3):477-86.

PMID: 25850893 PMC: 4779551. DOI: 10.1007/s11481-015-9604-2.

HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencing.

Ross L, Horton J, Hasan S, Brown J, Murphy D, DeJesus E PLoS One. 2014; 9(2):e89611.

PMID: 24586911 PMC: 3935917. DOI: 10.1371/journal.pone.0089611.

Risk behaviors among HIV-positive gay and bisexual men at party-oriented vacations.

Fisher M, Ramchand R, Bana S, Iguchi M J Stud Alcohol Drugs. 2012; 74(1):158-67.

PMID: 23200162 PMC: 3517259. DOI: 10.15288/jsad.2013.74.158.

References

Brenner B, Wainberg M, Salomon H, Rouleau D, Dascal A, Spira B . Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study. Int J Antimicrob Agents. 2000; 16(4):429-34. DOI: 10.1016/s0924-8579(00)00270-3. View

Little S, Holte S, Routy J, Daar E, Markowitz M, Collier A . Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002; 347(6):385-94. DOI: 10.1056/NEJMoa013552. View

Grant R, Hecht F, Warmerdam M, Liu L, Liegler T, Petropoulos C . Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 2002; 288(2):181-8. DOI: 10.1001/jama.288.2.181. View

Kosakovsky Pond S, Posada D, Gravenor M, Woelk C, Frost S . Automated phylogenetic detection of recombination using a genetic algorithm. Mol Biol Evol. 2006; 23(10):1891-901. DOI: 10.1093/molbev/msl051. View

Brenner B, Routy J, Petrella M, Moisi D, Oliveira M, Detorio M . Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol. 2002; 76(4):1753-61. PMC: 135882. DOI: 10.1128/jvi.76.4.1753-1761.2002. View

Drumright L, Patterson T, Strathdee S . Club drugs as causal risk factors for HIV acquisition among men who have sex with men: a review. Subst Use Misuse. 2006; 41(10-12):1551-601. DOI: 10.1080/10826080600847894. View

Colfax G, Vittinghoff E, Grant R, Lum P, Spotts G, Hecht F . Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. AIDS. 2007; 21(2):239-41. DOI: 10.1097/QAD.0b013e3280114a29. View

Colfax G, Vittinghoff E, Husnik M, McKirnan D, Buchbinder S, Koblin B . Substance use and sexual risk: a participant- and episode-level analysis among a cohort of men who have sex with men. Am J Epidemiol. 2004; 159(10):1002-12. DOI: 10.1093/aje/kwh135. View

Molitor F, Truax S, Ruiz J, Sun R . Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West J Med. 1998; 168(2):93-7. PMC: 1304836. View

10.

Bangsberg D, Acosta E, Gupta R, Guzman D, Riley E, Harrigan P . Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006; 20(2):223-31. DOI: 10.1097/01.aids.0000199825.34241.49. View

11.

Smith D, Moini N, Pesano R, Cachay E, Aiem H, Lie Y . Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection. Clin Infect Dis. 2007; 44(3):456-8. DOI: 10.1086/510748. View

12.

Smith D, Wong J, Shao H, Hightower G, Mai S, Moreno J . Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. J Infect Dis. 2007; 196(3):356-60. DOI: 10.1086/519164. View

13.

Ellis R, Childers M, Cherner M, Lazzaretto D, Letendre S, Grant I . Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis. 2003; 188(12):1820-6. DOI: 10.1086/379894. View

14.

Garcia-Lerma J, Nidtha S, Blumoff K, Weinstock H, Heneine W . Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci U S A. 2001; 98(24):13907-12. PMC: 61140. DOI: 10.1073/pnas.241300698. View

15.

Reback C, Larkins S, Shoptaw S . Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care. 2003; 15(6):775-85. DOI: 10.1080/09540120310001618621. View

16.

. Methamphetamine use and HIV risk behaviors among heterosexual men--preliminary results from five northern California counties, December 2001-November 2003. MMWR Morb Mortal Wkly Rep. 2006; 55(10):273-7. View

17.

Blick G, Kagan R, Coakley E, Petropoulos C, Maroldo L, Greiger-Zanlungo P . The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1-infected patient. J Infect Dis. 2007; 195(9):1250-9. DOI: 10.1086/512240. View

18.

Truong H, Grant R, McFarland W, Kellogg T, Kent C, Louie B . Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS. 2006; 20(17):2193-7. DOI: 10.1097/01.aids.0000252059.85236.af. View

19.

Moyle G, Fletcher C, Brown H, Mandalia S, Gazzard B . Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen. HIV Med. 2006; 7(4):243-7. DOI: 10.1111/j.1468-1293.2006.00363.x. View

20.

Semple S, Patterson T, Grant I . Motivations associated with methamphetamine use among HIV+ men who have sex with men. J Subst Abuse Treat. 2002; 22(3):149-56. DOI: 10.1016/s0740-5472(02)00223-4. View